Equities research analysts forecast that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report sales of $4.33 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Five Prime Therapeutics’ earnings, with estimates ranging from $2.83 million to $5.80 million. Five Prime Therapeutics reported sales of $5.77 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 25%. The company is expected to issue its next quarterly earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Five Prime Therapeutics will report full year sales of $17.37 million for the current fiscal year, with estimates ranging from $8.70 million to $26.00 million. For the next fiscal year, analysts expect that the firm will post sales of $51.25 million, with estimates ranging from $20.00 million to $139.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.09). Five Prime Therapeutics had a negative return on equity of 62.13% and a negative net margin of 842.84%. The business had revenue of $3.33 million during the quarter, compared to analysts’ expectations of $5.53 million.
Several equities research analysts have weighed in on FPRX shares. Roth Capital started coverage on Five Prime Therapeutics in a report on Wednesday, May 29th. They issued a “neutral” rating and a $10.00 price objective for the company. ValuEngine upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 6th. BidaskClub cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. Finally, Wells Fargo & Co cut Five Prime Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $35.00 to $10.00 in a research note on Monday, June 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $16.00.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC lifted its stake in shares of Five Prime Therapeutics by 1,691.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,374 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 5,074 shares during the period. BNP Paribas Arbitrage SA increased its position in Five Prime Therapeutics by 1,929.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,328 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 6,967 shares in the last quarter. Bailard Inc. bought a new position in Five Prime Therapeutics during the 1st quarter valued at approximately $141,000. Alambic Investment Management L.P. bought a new position in Five Prime Therapeutics during the 2nd quarter valued at approximately $69,000. Finally, Jane Street Group LLC bought a new position in Five Prime Therapeutics during the 4th quarter valued at approximately $110,000. Institutional investors own 81.75% of the company’s stock.
NASDAQ FPRX traded up $0.01 on Friday, hitting $5.79. The company’s stock had a trading volume of 488,200 shares, compared to its average volume of 379,125. Five Prime Therapeutics has a 52-week low of $4.89 and a 52-week high of $16.00. The company has a current ratio of 6.87, a quick ratio of 6.87 and a debt-to-equity ratio of 0.23. The company’s 50-day simple moving average is $5.56 and its 200 day simple moving average is $9.23. The firm has a market cap of $215.16 million, a P/E ratio of -1.40 and a beta of 2.58.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Recommended Story: Operating Income
Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.